



Essential research and critical manufacturing operations to continue at Syngene International in compliance with Government of India directives and classification as an “essential” industry

- **Syngene International temporarily suspends all non-essential operations to observe 21-day national lockdown**
- **Only employees critical to maintaining essential research and manufacturing will be on site, all other staff to ‘Work from Home’ in compliance with Government of India directive**

Bengaluru, March 25, 2020:

Syngene International has today announced that it has temporarily suspended part of its research activity at its Bengaluru and Hyderabad sites to ensure the maximum number of staff can actively observe the national 21-day lockdown.

Essential pharmaceutical manufacturing and research and clinical development projects will continue to operate in full compliance with government requirements.

During the lockdown period certain units that require daily housekeeping and maintenance in order to ensure safe operations and regulatory compliance will continue with minimum staffing levels. All other on-site activity will undergo a safe temporary shutdown procedure and be ready to return to full operation on 15 April 2020.

With research and manufacturing facilities located in Bengaluru, Mangaluru and Hyderabad, the company is continuously monitoring the situation and reviewing its plans to comply with regulations issued by the Government of India and the relevant state authorities.



Said Jonathan Hunt, Chief Executive Officer, Syngene International Ltd., *“At this time of national emergency, we are focusing on three priorities: ensuring all staff are well informed on the actions they can take to keep themselves and others safe; continuing to conduct essential research and manufacturing activities; and enabling as many staff as possible to play a full part in observing the 21 day national lockdown. Since the emergence of the coronavirus, we have focused on promoting good hygiene and social distancing practices at our sites, in our labs and offices and with our employees. Throughout the coming weeks we will strengthen these measures wherever possible. As a largely science-based population, we understand the complexity of this situation and are committed to playing our part in improving human health and in protecting the nation.”*

During the lockdown period, the only employees on site will be those needed to run essential operations, all other staff are expected to work from home and actively follow the requirements of the 21-day national lockdown.

All necessary measures to slow the spread of COVID-19 and help in ‘flattening of the curve’ have been taken. In addition to promoting good hygiene and introducing shift working and working from home, national and international business travel for our employees has been stopped, dining facilities have been segregated and seating density reduced, company transport has been scheduled to reduce the number of travellers per vehicle and virtual meetings are encouraged. A dedicated intranet site provides employees with important information related to COVID-19 guidelines and status updates.

These precautionary measures will remain in effect until further notice.

Said Jonathan Hunt, Chief Executive Officer, Syngene International Ltd., *“We support the important efforts of the authorities to contain, or slow, the spread of the virus.*



We will continue to monitor the situation and will deploy our business continuity arrangements to protect our employees and deliver essential work as the threat from the COVID-19 outbreak unfolds.”

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation-focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene’s clientele includes world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4000-strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speed up time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com.

Contact details

Investor Contact	Media Contact
Sapna Hb M: +917899911289 Fax: +91 80 2852 3423 E: Sapna.Hb@syngeneintl.com	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com